Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;44(9):3487-3495.
doi: 10.1007/s10067-025-07565-y. Epub 2025 Jul 30.

Synovial infiltrating immune cell heterogeneity associated with synovitis severity and systemic disease activity in rheumatoid arthritis: a cross-sectional study

Affiliations

Synovial infiltrating immune cell heterogeneity associated with synovitis severity and systemic disease activity in rheumatoid arthritis: a cross-sectional study

Peishi Rao et al. Clin Rheumatol. 2025 Sep.

Abstract

Background: Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by persistent synovitis. The synovial inflammation observed in RA exhibits significant heterogeneity among patients.

Objective: To examine the relationship between major immune cell infiltration profiles in synovium and both local synovitis and systemic manifestations of RA.

Methods: This cross-sectional study enrolled 22 RA patients (mean disease duration: 7.1 years). Synovial biopsies were assessed using the Krenn synovitis scoring system (no/low/high-grade) and immunohistochemical pathotyping (lympho-myeloid, diffuse-myeloid, pauci-immune). Clinical parameters, including the Disease Activity Score-28 (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and autoantibody status, were systematically analyzed.

Results: Immunohistochemical analysis identified three distinct synovial pathotypes, characterized by specific distributions of CD3⁺ T cells, CD68⁺ macrophages, CD20⁺ B cells, and CD138⁺ plasma cells. Synovitis severity, classified using the Krenn scoring system, demonstrated significant differences in synovial inflammation and stromal hyperplasia. High-grade synovitis exhibited significantly increased infiltration of CD20⁺ B cells (p = 0.025) and CD138⁺ plasma cells (p = 0.034) compared to non-inflamed tissues. Pathotype distribution analysis revealed a predominance of the pauci-immune subtype in the no-synovitis group (59.1%), whereas the lympho-myeloid subtype became progressively more prevalent with increasing synovitis severity (31.8% overall).ESR, CRP, and DAS28, were significantly correlated with synovial immune cell infiltration and synovitis severity, whereas no significant association was observed between synovitis and RA associated autoantibodies such as anti-cyclic citrullinated peptide (anti-CCP) or rheumatoid factor (RF).

Conclusion: These findings underscore the complex interactions between synovial infiltrating immune cells, synovitis severity, and systemic disease activity, providing valuable insights for the development of personalized RA management strategies. Key Points •This study characterizes synovial immune infiltrates in relation to synovitis severity and systemic disease activity in RA •High-grade synovitis, as assessed by the Krenn scoring system, is associated with increased infiltration of immune cells, such as CD20⁺ B cells and CD138⁺ plasma cells, contributing to more severe inflammation and joint destruction. •The distribution of synovial pathotypes (lympho-myeloid, diffuse-myeloid, pauci-immune) correlates with synovitis severity, providing insights into potential molecular subtypes that could influence clinical phenotypes and treatment responses in RA.

Keywords: Disease activity; Rheumatoid arthritis; Synovial immune cell; Synovitis.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards. Ethics approval and consent to participate: This study was approved by the Ethics Committee of Peking University People’s Hospital (approval no. 2021PHB257-001). Disclousure: The authors declare that there is no conflicts of interest.

References

    1. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038 - PubMed
    1. Holers VM, Kuhn KA, Demoruelle MK, Norris JM, Firestein GS, James EA et al (2022) Mechanism-driven strategies for prevention of rheumatoid arthritis. Rheumatol Autoimmun 2(3):109–119 - PubMed - PMC
    1. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA et al (2019) Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 78(11):1463–1471 - PubMed
    1. Buch MH (2018) Defining refractory rheumatoid arthritis. Ann Rheum Dis 77(7):966–969 - PubMed
    1. Emery P, McInnes IB, van Vollenhoven R, Kraan MC (2008) Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 47(4):392–398 - PubMed

MeSH terms

LinkOut - more resources